Please assess the completion status of the following clinical trial:

Trial Title: Statins for the Early Treatment of Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Initial presentation to the Emergency Department or University of Chicago MD office/Dialysis Center for current hospital admission~* Sepsis (ACCP/SCCM criteria)~  1. Clinically suspected infection as per the treating physician or confirmed infection~ 2. 2 or more of the following: Temperature 38ºC (100.4ºF)or 36ºC (96.8ºF), Heart rate (HR) \> 90/min, Respiratory rate (RR) \> 20/min or PaCO2 \< 32 mmHg, White blood cell count \> 12,000/mm3 or \< 4000/m3 or \> 10%immature neutrophils~* Initiation of antibiotics by treating physician for sepsis~* Hospitalized from the Emergency Department or University of Chicago MD office/Dialysis Center to an inpatient medical service (intensive care unit (ICU)or non-ICU service) OR admission to the medical ICU (MICU) from a non-ICU inpatient medical floor.~* Assent of the primary treating physician at the time of enrollment.~* The meeting of SIRS criteria is due to an infection as per the treating physician.~Exclusion Criteria:~* Pregnancy~* ALT \>3 times above the upper limit of normal~* Elevated creatine phosphokinase (CPK) (\>3 times the upper limit of normal)~* Concurrent treatment with any of the following drugs: daptomycin, fenofibrate, ketoconazole,triaconazole, amiodarone, clarithromycin, cyclosporine, erythromycin,nefazodone, niacin, protease inhibitors, telithromycin, verapamil,danazol, gemfibrozil~* History of allergy or intolerance to statins~* Greater than 16 hours after meeting inclusion criteria~* Use of 1 more doses of statins in the previous 4 weeks~* Clinical indication for treatment with statin during hospital admission (per treating physician)~* Sufficiently poor prognosis prior to enrollment that treating physicians have elected to employ comfort care or plan to discharge to hospice~* Transfer from surgical service to medical service~* Needing transfusion for either active bleeding or severe hemolysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Simvastatin 80 mg once daily PO (or via NG or G-tube)
- 2 (Type: PLACEBO_COMPARATOR): Identical-appearing placebo PO (or via NG or G-tube)

Based on this trial design, predict the completion outcome and termination type (if applicable).